Drug intelligence / Profile preview

hu3D7

Development stage: Preclinical
Modality: IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

hu3D7 is a humanized T cell receptor-like antibody developed for the treatment of cytomegalovirus (CMV) infection, particularly following transplantation. It functions by specifically recognizing and binding to the pCMV-pp65495-503/HLA-A2 complex presented on the surface of CMV-infected cells. This binding leads to the efficient targeting and eradication of these infected cells, primarily through the activation of CD8+ T cells and the subsequent release of cytotoxic molecules like granzyme B and perforin, thereby exerting its antiviral effect.

Targets

pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)

Beyond the preview

Go deeper on hu3D7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hu3D7.

Explore the full profile